
    
      This is a randomized phase II clinical trial. The objective of the study is to assess the
      efficacy of osimertinib combined with bevacizumab for LM from EGFR- mutant NSCLC. Patients
      were randomized with equal allocation to 80 mg of oral Osimertinib daily alone or with 7.5
      mg/kg of intravenous bevacizumab every 3 weeks. Study therapy continued until disease
      progression, unacceptable adverse event, or withdrawal of consent
    
  